These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 21965163)

  • 1. Clinical outcome and prognostic factors of sorafenib in Japanese patients with advanced renal cell carcinoma in general clinical practice.
    Tanigawa G; Kawashima A; Yamaguchi S; Nishimura K; Miyoshi S; Kajikawa J; Meguro N; Yosioka T; Oka T; Hara T; Takayama H; Nonomura N;
    Jpn J Clin Oncol; 2011 Nov; 41(11):1265-70. PubMed ID: 21965163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
    Yuasa T; Tsuchiya N; Urakami S; Horikawa Y; Narita S; Inoue T; Saito M; Yamamoto S; Yonese J; Fukui I; Nakano K; Takahashi S; Hatake K; Habuchi T
    BJU Int; 2012 May; 109(9):1349-54. PubMed ID: 21883864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study.
    Zhang H; Dong B; Lu JJ; Yao X; Zhang S; Dai B; Shen Y; Zhu Y; Ye D; Huang Y
    BMC Cancer; 2009 Jul; 9():249. PubMed ID: 19622166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics.
    Feinberg BA; Jolly P; Wang ST; Fortner B; Scott J; Gilmore J; Neary MP; Duh MS
    Med Oncol; 2012 Jun; 29(2):786-94. PubMed ID: 21479699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of sorafenib correlates with Memorial Sloan-Kettering Cancer Center (MSKCC) risk classification and bone metastasis in Chinese patients with metastatic renal cell carcinoma.
    Zhang Y; Li Y; Cai Y; Wang K; Li H
    Cell Oncol (Dordr); 2016 Feb; 39(1):15-21. PubMed ID: 26597814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma.
    Naito S; Tsukamoto T; Murai M; Fukino K; Akaza H
    BJU Int; 2011 Dec; 108(11):1813-9. PubMed ID: 21481133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib in advanced clear-cell renal-cell carcinoma.
    Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Siebels M; Negrier S; Chevreau C; Solska E; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Freeman S; Schwartz B; Shan M; Simantov R; Bukowski RM;
    N Engl J Med; 2007 Jan; 356(2):125-34. PubMed ID: 17215530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
    Zimmermann K; Schmittel A; Steiner U; Asemissen AM; Knoedler M; Thiel E; Miller K; Keilholz U
    Oncology; 2009; 76(5):350-4. PubMed ID: 19321976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial.
    Eisen T; Oudard S; Szczylik C; Gravis G; Heinzer H; Middleton R; Cihon F; Anderson S; Shah S; Bukowski R; Escudier B;
    J Natl Cancer Inst; 2008 Oct; 100(20):1454-63. PubMed ID: 18840822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.
    Escudier B; Szczylik C; Hutson TE; Demkow T; Staehler M; Rolland F; Negrier S; Laferriere N; Scheuring UJ; Cella D; Shah S; Bukowski RM
    J Clin Oncol; 2009 Mar; 27(8):1280-9. PubMed ID: 19171708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib.
    Nakano K; Komatsu K; Kubo T; Natsui S; Nukui A; Kurokawa S; Kobayashi M; Morita T
    Jpn J Clin Oncol; 2013 Oct; 43(10):1023-9. PubMed ID: 23956442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings.
    Beck J; Procopio G; Bajetta E; Keilholz U; Negrier S; Szczylik C; Bokemeyer C; Bracarda S; Richel DJ; Staehler M; Strauss UP; Mersmann S; Burock K; Escudier B
    Ann Oncol; 2011 Aug; 22(8):1812-23. PubMed ID: 21324953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy and prognostic factors of tumor progression in Japanese patients with advanced renal cell carcinoma treated with sorafenib.
    Kondo T; Nakazawa H; Oya M; Kimura G; Fujii Y; Hatano T; Kawata N; Kume H; Morita M; Nakajima K; Ohno Y; Okegawa T; Takahashi S; Wakumoto Y; Horie S; Yamaguchi R; Saito K; Murakami M
    Jpn J Clin Oncol; 2015 Mar; 45(3):274-80. PubMed ID: 25420693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.
    Rini B; Szczylik C; Tannir NM; Koralewski P; Tomczak P; Deptala A; Dirix LY; Fishman M; Ramlau R; Ravaud A; Rogowski W; Kracht K; Sun YN; Bass MB; Puhlmann M; Escudier B
    Cancer; 2012 Dec; 118(24):6152-61. PubMed ID: 22692704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency.
    Khan G; Golshayan A; Elson P; Wood L; Garcia J; Bukowski R; Rini B
    Ann Oncol; 2010 Aug; 21(8):1618-1622. PubMed ID: 20089567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma.
    Trask PC; Bushmakin AG; Cappelleri JC; Tarazi J; Rosbrook B; Bycott P; Kim S; Stadler WM; Rini B
    J Cancer Surviv; 2011 Sep; 5(3):255-62. PubMed ID: 21476015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience with sorafenib and the elderly patient.
    Dutcher JP; Tannir N; Bellmunt J; Escudier B
    Med Oncol; 2010 Dec; 27(4):1359-70. PubMed ID: 20043216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.
    Garcia JA; Hutson TE; Elson P; Cowey CL; Gilligan T; Nemec C; Dreicer R; Bukowski RM; Rini BI
    Cancer; 2010 Dec; 116(23):5383-90. PubMed ID: 20806321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.